DEPUY TO FINANCE ACQUISITIONS WITH PROCEEDS FROM $250 MIL. INITIAL PUBLIC OFFERING; SPIN-OFF FROM CORANGE LTD. OUTLINED IN AUG. 1 SEC FILING
This article was originally published in The Gray Sheet
Orthopedic devices and supplies producer DePuy plans to use proceeds from a $250 mil. initial public offering to expand its business through acquisitions, according to a registration statement filed with the Securities and Exchange Commission Aug. 1. The offering, to be underwritten by Morgan Stanley, Bear Stearns, Cowen & Co. and Furman Selz, would spin off at least a portion of the firm's ownership from its current parent company, Corange Limited.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.